COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,582 Articles (22,415 medRxiv, 8,167 bioRxiv)

Most recent first Previous |  Page 1000: Articles 9991-10000  | Next

Long-read RNA sequencing identifies polyadenylation elongation and differential transcript usage of host transcripts during SARS-CoV-2 in vitro infection
Chang, J. J.-Y., Gleeson, J., Rawlinson, D., Pitt, M. E., De Paoli-Iseppi, R., Zhou, C., Mordant, F. L., Londrigan, S. L., Clark, M. B., Subbarao, K., Stinear, T. P., Coin, L. J. M.
10.1101/2021.12.14.472725 — Posted: 2021-12-15
Potential inhibitors for blocking the interaction of the coronavirus SARS-CoV-2 spike protein and its host cell receptor ACE2
Li, C., Zhou, H., Guo, L., Xie, D., He, H., Zhang, H., Liu, Y., Peng, L., Zheng, L., Lu, W., Mei, Y., Liu, Z., Huang, J., Wang, M., Shu, D., Ding, L., Lang, Y., Luo, F., Wang, J., Huang, B., Huang, P., Gao, S., Chen, J., Qian, C.-N.
10.1101/2021.12.14.472545 — Posted: 2021-12-15
A comprehensive examination of ACE-2 receptor and prediction of spike glycoprotein and ACE-2 interaction based on in silico analysis of ACE-2 receptor
Ozgenturk, N. O., Aktas, E.
10.1101/2021.12.14.472331 — Posted: 2021-12-15
Evidence for a mouse origin of the SARS-CoV-2 Omicron variant
Wei, C., Shan, K.-J., Wang, W., Zhang, S., Huan, Q., Qian, W.
10.1101/2021.12.14.472632 — Posted: 2021-12-15 Discussion: Onsite
Genomic determinants of Furin cleavage in diverse European SARS-related bat coronaviruses
Sander, A.-L., Moreira-Soto, A., Yordanov, S., Toplak, I., Balboni, A., Ameneiros, R. S., Corman, V. M., Drosten, C., Drexler, J. F.
10.1101/2021.12.15.472779 — Posted: 2021-12-15
Metalloproteinase-dependent and TMPRSS2-independnt cell surface entry pathway of SARS-CoV-2 requires the furin-cleavage site and the S2 domain of spike protein
Yamamoto, M., Gohda, J., Kobayashi, A., Tomita, K., Hirayama, Y., Koshikawa, N., Seiki, M., Semba, K., Akiyama, T., Kawaguchi, Y., Inoue, J.-i.
10.1101/2021.12.14.472513 — Posted: 2021-12-15
Booster of mRNA-1273 Vaccine Reduces SARS-CoV-2 Omicron Escape from Neutralizing Antibodies
Doria-Rose, N., Shen, X., Schmidt, S. D., O'Dell, S., McDanal, C., Feng, W., Tong, J., Eaton, A., Maglinao, M., Tang, H., Atmar, R. L., Lyke, K. E., Wang, L., Zhang, y., Gaudinski, M. R., Black, W. P., Gordon, I., Guech, M., Ledgerwood, J. E., Misasi, J. N., Widge, A., Roberts, P. C., Beigel, J., Korber, B., Pajon, R., Mascola, J. R., Montefiori, D. C.
10.1101/2021.12.15.21267805 — Posted: 2021-12-15 Discussion: Onsite
SARS-CoV-2 Omicron: reduction of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern
Aggarwal, A., Ospina Stella, A., Walker, G., Akerman, A., Milogiannakis, V., Hoppe, A. C., Mathivanan, V., Fichter, C., McAllery, S., Amatayakul-Chantler, S., Roth, N., Coppola, G., Munier, M. L., Darley, D. R., Khoury, D. S., Foster, C. S. P., Lu, Y., Schofield, P., Jackson, J., Henry, J., Mazigi, O., Jaeck, H.-M., Langles, D., Cromer, D., Davenport, M. P., Christ, D., Matthews, G., Rawlinson, W., Kelleher, A. D., Turville, S. G.
10.1101/2021.12.14.21267772 — Posted: 2021-12-15
Clinical characteristics with inflammation profiling of Long-COVID and association with one-year recovery following hospitalisation in the UK: a prospective observational study
Evans, R. A., Leavy, O. C., Richardson, M., Elneima, O., McAuley, H. J. C., Shikotra, A., Singapuri, A., Sereno, M., Saunders, R. M., Harris, V. C., Aul, R., Beirne, P., Bolton, C. E., Brown, J. S., Choudhury, G., Diar Bakerly, N., Easom, N., Echevarria, C., Fuld, J., Hart, N., Hurst, J. R., Jones, M., Parekh, D., Pfeffer, P., Rahman, N. M., Rowland-Jones, S., Shah, A. M., Wootton, D. G., Chalder, T., Davies, M. J., De Soyza, A., Greenhalf, W., Greening, N. J., Heaney, L. G., Heller, S., Howard, L., Jacob, J., Jenkins, R. G., Lord, J. M., Man, W. D.-C., McCann, G. P., Neubauer, S., Openshaw, P. J., Porter, J., Quint, J., Rowland, M. J., Scott, J., Semple, M. G., Singh, S. J., Toshner, M., Lewis, K., Briggs, A., Docherty, A. B., Kerr, S., Lone, N. I., Sheikh, A., Thorpe, M., Zheng, B., Chalmers, J. D., Ho, L.-P., Horsley, A., Marks, M., Poinasamy, K., Raman, B., Harrison, E. M., Wain, L. V., Brightling, C. E., PHOSP-COVID Collaborative Group
10.1101/2021.12.13.21267471 — Posted: 2021-12-15
In silico evidence of superantigenic features in ORF8 protein from COVID-19
Gomez-Icazbalceta, G., Hussain, Z., Velez-Alavez, M.
10.1101/2021.12.14.472240 — Posted: 2021-12-14

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).